Skip to main content

RETRACTED ARTICLE: Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice

This article was retracted on 20 September 2022

This article has been updated


Egypt has the highest hepatitis C virus (HCV) prevalence in the world. Sofosbuvir is a new highly effective drug for treatment of HCV infection. Compared to previous treatments, sofosbuvir-based regimens provide a higher cure rate, fewer side effects, and a two- to fourfold reduced duration of therapy. The aim of this study was to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir plus ribavirin in Egyptian patients with liver cirrhosis due to chronic HCV infection. We studied 2400 cirrhotic Egyptian patients with chronic HCV infection who were treated with dual therapy with sofosbuvir and ribavirin for 24 weeks. Efficacy was determined by assessment of serum HCV RNA. Any adverse events during treatment were recorded. Two thousand four hundred cirrhotic Egyptian patients with chronic HCV infection treated with sofosbuvir and ribavirin for 24 weeks were enrolled in the study. The mean age of the studied group (± SD) was 53.9 ± 6.5 years, 1549 (64.54%) were males, all were cirrhotic patients, 3.41% were treatment-experienced, the baseline mean HCV RNA concentration was 4.33 × 106 IU/mL, and 94.37% of the patients had completed the full course of therapy. The overall SVR12 rate was 71.2%. The most common adverse events were fatigue, myalgia, headache, insomnia, and anemia. One hundred thirty-five (5.63%) patients stopped treatment permanently due to the appearance of complications that prevented continuation of treatment. The sofosbuvir and ribavirin combination is safe and effective in treatment of HCV patients with liver cirrhosis. However, further studies are needed to establish the optimal treatment regimen for those cases.

This is a preview of subscription content, access via your institution.

Fig. 1

Change history

  • 20 May 2022

    Editor's Note: The Editor-in-Chief is currently investigating this article as concerns have been raised about the reporting of this clinical trial. Further editorial action will be taken as appropriate once the investigation into the concerns is complete and all parties have been given an opportunity to respond in full.

  • 20 September 2022

    This article has been retracted. Please see the Retraction Notice for more detail:


  1. Ahmed OA, Kaisar HH, Hawash N et al (2017) Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in treatment of a cohort of Egyptian patients with hepatitis C virus infection. Infect Disord Drug Targets 17(2):95–100

    Article  CAS  Google Scholar 

  2. McOmish F, Yap PL, Dow BC et al (1994) Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 32:884–892

    Article  CAS  Google Scholar 

  3. Khattab MA, Ferenci P, Hadziyannis SJ et al (2011) Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 54:1250–1262

    Article  Google Scholar 

  4. Kamal SM, Nasser IA (2008) Hepatitis C genotype 4: what we know and what we don’t yet know. Hepatology 47:1371–1383

    Article  CAS  Google Scholar 

  5. Gower E, Estes C, Blach S et al (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:45–57

    Article  Google Scholar 

  6. AbdElrazek AE, Bilasy SE, Elbanna AE et al (2014) Prior to the oral therapy, what do we know about HCV-4 in Egypt: a randomized survey of prevalence and risks using data mining computed analysis. Medicine (Baltimore) 93:e204

    Article  Google Scholar 

  7. Smith DB, Bukh J, Kuiken C et al (2014) Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment Web resource. Hepatology 59:318–327

    Article  Google Scholar 

  8. Kamal SM (2007) Improving outcome in patients with hepatitis C virus genotype 4. Am J Gastroenterol 102:2582–2588

    Article  CAS  Google Scholar 

  9. Abdel-Razek W, Waked I (2015) Optimal therapy in genotype 4 chronic hepatitis C: finally cured? Liver Int 35(Suppl. 1):27–34

    Article  CAS  Google Scholar 

  10. Cholongitas E, Papatheodoridis GV (2014) Sofosbuvir: a novel oral agent for chronic hepatitis C. Ann Gastroenterol. 27(4):331–337

    PubMed  PubMed Central  Google Scholar 

  11. AASLD/IDSA/IAS-USA (2014) Recommendations for testing, managing, and treating hepatitis C. Accessed 24 April 2014

  12. Tran TT (2012) A review of standard and newer treatment strategies in hepatitis C. Am J Manag Care 18(14 Suppl):S340–S349

    PubMed  Google Scholar 

  13. Bourlière M, Khaloun A, Wartelle-Bladou C et al (2012) Future treatment of patients with HCV cirrhosis. Liver Int 32(Suppl 1):113–119

    Article  Google Scholar 

  14. Manns M, Vierling JM, Bacon BR et al (2013) High sustained viral response at 12- and 24-week follow-up of MK-7152 with pegylated interferon alfa-2a and ribavirin in HCV genotype 1 treatment-naive non-cirrhotic patients. J Hepatol 58(Suppl N1):1

    Google Scholar 

  15. Lawitz E, Gane E, Lalezari J et al (2013) High concordance of SVR4, SVR12, SVR24 in patients with HCV infection who have received treatment with sofosbuvir. The International Liver Congress, Amsterdam, p P848

    Google Scholar 

  16. Elwan N, Elfert A, Abd-Elsalam S et al (2016) Study of hepatic steatosis index in patients with chronic HCV infection. Int J Curr Microbiol App Sci 5(5):266–274

    Article  CAS  Google Scholar 

  17. Ruane PJ, Ain D, Stryker R et al (2015) Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 62(5):1040–1046

    Article  CAS  Google Scholar 

  18. Zeuzem S, Dusheiko GM, Salupere R et al (2014) Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 370:1993–2001

    Article  Google Scholar 

  19. Afdhal N, Reddy KR, Nelson DR et al (2014) Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370:1483–1493

    Article  CAS  Google Scholar 

  20. Sulkowski MS, Poordad F, Manns MP et al (2013) Anemia during treatment with peg interferon alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology 57:974–984

    Article  CAS  Google Scholar 

  21. European Association for the Study of the Liver diseases (2014) EASL recommendations on treatment of hepatitis C. J Hepatol 61:373–395

    Article  Google Scholar 

  22. AASLD/IDSA HCV Guidance Panel (2015) Hepatitis C guidance: AASLD IDSA recommendations for testing, managing and treating adults infected with hepatitis C virus. Hepatology 62:932–954

    Article  Google Scholar 

  23. Esmat GE, Shiha G, Omar RF et al (2014) Sofosbuvir plus ribavirin in the treatment of Egyptian patients with chronic genotype 4 HCV. Hepatology 60(4 suppl):133A

    Google Scholar 

  24. Doss W, Shiha G, Hassany M et al (2015) Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol 63(3):581–585

    Article  CAS  Google Scholar 

  25. Dabbous HM, Montasser IF, Sakr MA et al (2016) Safety, efficacy, and tolerability of sofosbuvir and ribavirin in management of recurrent hepatitis C virus genotype 4 after living donor liver transplant in Egypt: What have we learned so far? Hepat Mon 16(5):e35339

    Article  Google Scholar 

  26. Halfon P, Mohamed S, Penaranda G et al (2016) Hepatitis C genotype 4R resistance-associated polymorphisms: the achilles heel of the nonstructural 5A inhibitors? Hepatology 64(2):697–698

    Article  Google Scholar 

  27. Foster GR, Pianko S, Brown A et al (2015) Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 149(6):1462–1470

    Article  CAS  Google Scholar 

  28. Welker MW, Luhne S, Lange CM et al (2016) Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment. J Hepatol 64(4):790–799. doi:10.1016/j.jhep.2015.11.034

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Sherief Abd-Elsalam.

Ethics declarations

Source of support


Conflict of interest

All authors declared that they have no conflict of interest.

Additional information

Handling Editor: Michael Carpenter.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abd-Elsalam, S., Sharaf-Eldin, M., Soliman, S. et al. RETRACTED ARTICLE: Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice. Arch Virol 163, 51–56 (2018).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: